WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM, Inc. (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced the grant of an inducement award to its newly appointed Chief Scientific Officer, James W. Lillie, Ph.D. The award was approved by OvaScience’s Board of Directors on March 6, 2018 as an inducement material to Dr. Lillie entering into employment with the Company, as permitted under Nasdaq Listing Rule 5635(c)(4). The inducement grant to Dr. Lillie consisted of an option to purchase up to 357,057 shares of common stock. The stock options are exercisable at a price of $1.02 per share, equal to the closing price per share of OvaScience’s common stock as reported by Nasdaq on March 6, 2018. The stock options vest over four years, with 25% of such options vesting on January 16, 2019 and 6.25% of such options vesting at the end of each subsequent quarter thereafter, subject to Dr. Lillie’s continued service with the Company through the applicable vesting dates.
OvaScienceSM, Inc. (NASDAQ:OVAS) is a fertility company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC℠) cells – immature egg cells found within the outer ovarian cortex. OvaScience is developing the OvaPrime℠ treatment, which could increase a woman’s egg reserve and the OvaTure℠ treatment, a potential in vitro fertilization (IVF) treatment that could help a woman produce new fertilizable eggs without hormone injections. OvaScience’s AUGMENT℠ treatment is a fertility option designed to improve IVF success rates. OvaScience treatments are not available in the United States. For more information, visit www.ovascience.com.